8247 Stock Overview
Manufactures, sells, and distributes in-vitro diagnostic reagents in Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Biosino Bio-Technology and Science Incorporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.62 |
| 52 Week High | HK$1.38 |
| 52 Week Low | HK$0.26 |
| Beta | -0.84 |
| 1 Month Change | -26.19% |
| 3 Month Change | 0% |
| 1 Year Change | -31.11% |
| 3 Year Change | -60.51% |
| 5 Year Change | -63.10% |
| Change since IPO | -77.25% |
Recent News & Updates
Recent updates
Biosino Bio-Technology and Science Incorporation's (HKG:8247) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 23
Biosino Bio-Technology and Science Incorporation's (HKG:8247) Business And Shares Still Trailing The Industry
Oct 31Biosino Bio-Technology and Science Incorporation's (HKG:8247) 26% Dip In Price Shows Sentiment Is Matching Revenues
Jun 27Shareholders Will Probably Be Cautious Of Increasing Biosino Bio-Technology and Science Incorporation's (HKG:8247) CEO Compensation At The Moment
Jun 21Biosino Bio-Technology and Science Incorporation (HKG:8247) Held Back By Insufficient Growth Even After Shares Climb 46%
Apr 22Is Biosino Bio-Technology and Science Incorporation (HKG:8247) Using Debt In A Risky Way?
Apr 01Biosino Bio-Technology and Science Incorporation's (HKG:8247) 31% Dip In Price Shows Sentiment Is Matching Revenues
Feb 08Some Confidence Is Lacking In Biosino Bio-Technology and Science Incorporation (HKG:8247) As Shares Slide 38%
Jul 31Shareholder Returns
| 8247 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 14.8% | 4.1% | 1.5% |
| 1Y | -31.1% | 55.0% | 13.8% |
Return vs Industry: 8247 underperformed the Hong Kong Biotechs industry which returned 55% over the past year.
Return vs Market: 8247 underperformed the Hong Kong Market which returned 13.8% over the past year.
Price Volatility
| 8247 volatility | |
|---|---|
| 8247 Average Weekly Movement | 19.3% |
| Biotechs Industry Average Movement | 14.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in HK Market | 15.5% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 8247's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 8247's weekly volatility has increased from 12% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 499 | Peng Chen | www.sinobio.com.cn |
Biosino Bio-Technology and Science Incorporation, together with its subsidiaries, manufactures, sells, and distributes in-vitro diagnostic reagents in Mainland China. It offers clinical chemistry reagents, including single and double reagents, calibrators, QC products, and washing solution detergents; Elisa kits; rapid tests; and analyzers. The company also provides medical and medical inspection services; produces and sells medical instruments; and researches and develops, sells, and distributes biological reagents and instruments.
Biosino Bio-Technology and Science Incorporation Fundamentals Summary
| 8247 fundamental statistics | |
|---|---|
| Market cap | HK$89.72m |
| Earnings (TTM) | -HK$45.67m |
| Revenue (TTM) | HK$282.49m |
0.3x
P/S Ratio-2.0x
P/E RatioIs 8247 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8247 income statement (TTM) | |
|---|---|
| Revenue | CN¥263.07m |
| Cost of Revenue | CN¥154.67m |
| Gross Profit | CN¥108.40m |
| Other Expenses | CN¥150.93m |
| Earnings | -CN¥42.53m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 41.21% |
| Net Profit Margin | -16.17% |
| Debt/Equity Ratio | 85.0% |
How did 8247 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 17:58 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biosino Bio-Technology and Science Incorporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| T. J. Hsu | KGI Securities Co. Ltd. |